KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Leukemia and Lymphoma

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/10428194.2017.1361025PMID 28792268
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acute Myeloid Leukemia

  2020cited by this paper
• International System for Human Cytogenetic Nomenclature

  2020cited by this paper
• Prognostic Significance of KIT Mutations in Core-Binding Factor Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

  2016cited by this paper
• The genomic landscape of core-binding factor acute myeloid leukemias

  2016cited by this paper
• Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial

  2015influential reference
• Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.

  2015cited by this paper
• Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population

  2015cited by this paper
• Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.

  2014cited by this paper
• Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002/01 trial: screening and prognostic impact of c-KIT mutations

  2014cited by this paper
• Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia

  2014cited by this paper
• The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia

  2013cited by this paper
• Core binding factor acute myeloid leukaemia and c-KIT mutations.

  2013cited by this paper
• Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?

  2013cited by this paper
• Integrative analysis of prognostic factors in Chinese core binding factor leukemia.

  2012cited by this paper
• WT1 mutations and single nucleotide polymorphism rs16754 analysis of patients with pediatric acute myeloid leukemia in a Chinese population

  2012cited by this paper
• Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.

  2010influential reference
• FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

  2010cited by this paper
• Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China

  2009cited by this paper
• Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population

  2009cited by this paper
• Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples

  2008influential reference
• Cooperating gene mutations in acute myeloid leukemia: a review of the literature

  2008influential reference
• The incidence and clinical significance of nucleophosmin mutations in childhood AML.

  2007cited by this paper
• KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group.

  2006influential reference
• Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.

  2006cited by this paper
• The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations

  2006cited by this paper
• Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)

  2006cited by this paper
• Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study.

  2006cited by this paper
• Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study.

  2006cited by this paper
• Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells

  2005cited by this paper
• Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000

  2005cited by this paper
• Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.

  2005cited by this paper
• KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor.

  2005cited by this paper
• Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia

  2005influential reference
• Articles on similar topics can be found in the following Blood collections

  2004cited by this paper
• Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461.

  2004cited by this paper
• Acute myeloid leukemia

  2004cited by this paper
• Pilot study of idarubicin-based intensive-timing induction therapy for children with previously untreated acute myeloid leukemia: Children's Cancer Group Study 2941.

  2004cited by this paper
• High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

  2004cited by this paper
• Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia.

  2003cited by this paper
• Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias

  2003cited by this paper
• Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias.

  2002cited by this paper
• Core binding factor genes and human leukemia.

  2002cited by this paper
• Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

  2002cited by this paper
• Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study.

  2001cited by this paper
• The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia

  1999cited by this paper
• THE AML1‐ETO CHIMAERIC TRANSCRIPTION FACTOR IN ACUTE MYELOID LEUKAEMIA: BIOLOGY AND CLINICAL SIGNIFICANCE

  1999cited by this paper
• The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

  1998cited by this paper
• Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group.

  1996cited by this paper
• Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase.

  1996cited by this paper
• Localization of the human c-kit protooncogene on the q11–q12 region of chromosome 4

  1988cited by this paper

• Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial (JCCG AML-12).

  2026cites this paper
• Prognostic significance of cytogenetic and molecular features in pediatric acute myeloid leukemia: a meta-analysis

  2025cites this paper
• Beyond “favorable”: early molecular response and outcomes in pediatric RUNX1::RUNX1T1 AML

  2025cites this paper
• Impact of Somatic Gene Mutations on Prognosis Prediction in De Novo AML: Unraveling Insights from a Systematic Review and Meta-Analysis

  2025cites this paper
• Molecular genetics profiling of core-binding factor acute myeloid leukemia in pediatrics

  2025cites this paper
• Prognostic Factors of Pediatric Acute Myeloid Leukemia Patients with t(8;21) (q22;q22): A Single-Center Retrospective Study

  2024cites this paper
• Adverse prognostic impact of KIT exon 17 mutations despite negative flow cytometric measurable residual disease in pediatric acute myeloid leukemia with RUNX1::RUNX1T1

  2024cites this paper
• Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16)

  2023cites this paper
• KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1

  2023cites this paper
• Clinical impact of c-KIT and CEBPA mutations in 33 patients with corebinding factor (Non-M3) acute myeloid leukemia.

  2023cites this paper
• Clinical and Demographic Characteristics of Cutaneous Mastocytosis in Childhood: Single-center Experience

  2021cites this paper
• KIT is required for fetal liver erythropoiesis but dispensable for angiogenesis

  2021cites this paper
• Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia.

  2021cites this paper
• KIT Is Required for Fetal Liver Hematopoiesis

  2021cites this paper
• Targeted Therapy in Pediatric AML: An Evolving Landscape

  2021cites this paper
• The Prognostic Significance of c-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia.

  2021cites this paper
• Influence of KIT mutations on prognosis of pediatric patients with core-binding factor acute myeloid leukemia: a systematic review and meta-analysis

  2020influential citation
• A comparison of the therapeutic, toxic, and side effects of cytarabine combined with different doses of idarubicin in the treatment of children with acute myeloid leukemia

  2020cites this paper
• Prognostic Impact of Extramedullary Infiltration in Pediatric Low-risk Acute Myeloid Leukemia: A Retrospective Single-center Study Over 10 Years.

  2020cites this paper
• [Clinical features and prognosis of core binding factor acute myeloid leukemia in children].

  2020cites this paper
• 二代测序检测克隆性基因突变对RUNX1-RUNX1T1阳性急性髓系白血病的预后价值

  2020cites this paper
• Core binding factor acute myeloid leukemia: Advances in the heterogeneity of KIT, FLT3, and RAS mutations (Review).

  2020cites this paper
• Cytological and spectroscopic characteristics of c‐KIT N822K mutation in core binding factor acute myeloid leukemia cells

  2020cites this paper
• Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia

  2019cites this paper
• Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia

  2019cites this paper
• Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.

  2019cites this paper
• GATA2 mutations and overexpression in pediatric acute myeloid leukemia

  2019cites this paper
• Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)

  2018cites this paper